Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Income from Continuing Operations (2016 - 2025)

Lineage Cell Therapeutics' Income from Continuing Operations history spans 16 years, with the latest figure at 6155000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 89.38% year-over-year to 6155000.0; the TTM value through Dec 2025 reached 34928000.0, down 87.97%, while the annual FY2025 figure was 63367000.0, 241.01% down from the prior year.
  • Income from Continuing Operations reached 6155000.0 in Q4 2025 per LCTX's latest filing, down from 3420000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1448000.0 in Q1 2021 to a low of 28009000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 7177850.0, with a median of 6071500.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 82.82% in 2021 against a maximum downside of 2946.44% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 28009000.0 in 2021, then skyrocketed by 77.43% to 6321000.0 in 2022, then grew by 25.42% to 4714000.0 in 2023, then soared by 31.06% to 3250000.0 in 2024, then crashed by 89.38% to 6155000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Income from Continuing Operations are 6155000.0 (Q4 2025), 3420000.0 (Q3 2025), and 19326000.0 (Q2 2025).